5-HT1A receptors are Gi-coupled serotonin receptors expressed both presynaptically (as autoreceptors) and postsynaptically throughout the brain. These receptors modulate serotoninergic tone, influence mood, anxiety, and cognitive function. 5-HT1A receptor dysfunction is implicated in depression, anxiety disorders, and neurodegenerative diseases.
- Location: Raphe nuclei cell bodies and dendrites
- Function: Negative feedback - inhibit serotonin release
- Somatodendritic: Control firing rate
- Terminal: Modulate release
- Location: Cortex, hippocampus, amygdala
- Function: Modulate target neuron activity
- Excitatory: Disinhibition via Gi signaling
- Network effects: Modulate entire circuits
| Marker |
Type |
Function |
| HTR1A |
Receptor |
5-HT1A receptor |
| TPH2 |
Enzyme |
Tryptophan hydroxylase 2 |
| SLC6A4 |
Transporter |
Serotonin transporter |
| GNAQ |
G-protein |
Gαq subunit |
| ADCY |
Enzyme |
Adenylyl cyclase |
| CREB |
Transcription |
cAMP response element binding |
- Depression: 5-HT1A activation produces anxiolytic effects
- Anxiety: Reduce anxiety-like behavior
- Emotional processing: Amygdala modulation
- Stress response: Modulate HPA axis
- Working memory: PFC modulation
- Attention: Cortical processing
- Learning: Hippocampal plasticity
- Decision making: Orbitofrontal cortex
- Analgesia: Spinal and supraspinal sites
- Peripheral sensation: Nociceptor modulation
- Chronic pain: Dysregulation contributes
5-HT1A in depression:
- Receptor downregulation: Reduced expression
- Autoreceptor dysfunction: Impaired feedback
- Treatment target: 5-HT1A agonists
- Delayed onset: Receptor changes take time
5-HT1A in anxiety:
- Anxiolytic effects: Reduce anxiety
- Panic disorder: 5-HT1A agonists reduce attacks
- PTSD: Modulate fear circuits
- Social anxiety: Amygdala normalization
5-HT1A in AD:
- Early loss: Receptor decline before pathology
- Cognitive effects: Memory modulation
- Behavioral symptoms: Agitation, aggression
- Treatment: 5-HT1A partial agonists
5-HT1A in PD:
- Non-motor symptoms: Depression, anxiety
- L-dopa dyskinesia: 5-HT1A reduces
- Motor modulation: Minor direct effects
- Early decline: With aging
- Pathology effects: Tau, Aβ reduce
- Region-specific: Hippocampus vulnerable
- Reduced coupling: In disease states
- Signaling dysfunction: Downstream effects
- Second messenger: cAMP reductions
- ADAR editing: Alters receptor function
- Efficiency variations: Individual differences
- Functional consequences: Altered pharmacology
| Region |
Density |
Function |
| Raphe nuclei |
High |
Autoreceptor |
| Hippocampus CA1 |
High |
Memory |
| Cortex layer II |
Moderate |
Cognition |
| Amygdala |
Moderate |
Emotion |
- 5-HT1A agonists: Buspirone, tandospirone
- Partial agonists: Optimize response
- SSRI combination: Faster onset
- Allosteric modulators: Greater specificity